ArticleBMC ophthalmology2026
The effects of mirabegron and anticholinergic treatment on anterior segment and pupillary responses in overactive bladder syndrome.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the effect of tolterodine and mirabegron on anterior chamber parameters and static pupillometry measurements in overactive bladder (OAB) patients and to compare these results with those of healthy controls.
methodsThis study included 35 patients with OAB who were planned to be treated with tolterodine, 35 patients with OAB who were planned to be treated with mirabegron, and 35 healthy control subjects. All the participants underwent full ophthalmic examination and scanning with Sirius topographer (CSO, Firenze, Italy) before and at 1 and 3 months in both the control and the mirabegron and anticholinergic groups after treatment. In addition, central corneal thickness (CCT), anterior chamber depth, angle, and volume were recorded.
resultsThe mean intraocular pressure (IOP) increased significantly in the first month of treatment after mirabegron (p = 0.034). Anterior chamber depth increased significantly in the mirabegron group at the third month of treatment compared to pretreatment (p = 0.039). Higher mesopic and photopic pupil diameters were found at 1 and 3 months after tolterodine compared to baseline (p < 0.05 for all). Higher scotopic pupil diameters were found at 1 month after mirabegron (p = 0.002). No statistical differences were found between pretreatment and posttreatment static pupillometry and anterior chamber parameter measurements in the control group (p > 0.05 for all).
conclusionOur study demonstrated that both tolterodine and mirabegron affected pupil diameters under different light conditions. They also caused changes in anterior chamber parameters. However, given the modest magnitude of these changes and the dynamic nature of pupil diameter, caution should be exercised in the clinical interpretation of the results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.